ClinicalTrials.gg
RecruitingNCT06777979Updated May 19, 2026

CD19-CD22-Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy for Pediatric Patients With Acute Lymphoblastic Leukemia

A Phase 1 interventional study of Fludarabine and Cyclophosphamide in Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia and Recurrent B Acute Lymphoblastic Leukemia, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by St. Jude Children's Research Hospital · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
Up to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 136 studies testing fludarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 24 open to participants now, 36 under way, 2 of them phase 3. fludarabine · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
80th of 134
30 · median 40
Started
2025
with 2 others
Phase 1
34 of 136
8 open now
Primary completion
2030-01
later than 26 of 35 live
Registered
131st of 136
by date
Lead sponsor
5 of 136
St. Jude Children's Research Hospital

Among the 136 studies testing fludarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 80th largest by planned enrollment of the 134 interventional ones that give a count, is one of 3 that started in 2025, is one of 34 in phase 1, reaches primary completion later than 26 of the 35 other live ones, and was the 131st registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

24 of the 136 studies testing fludarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 24 open studies →

About fludarabine

fludarabine: first FDA approval 1991 (FLUDARA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: Up to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing fludarabine in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

This study is a phase I study designed to evaluate the safety of CD19-CD22-CAR T cells.

Primary Objective:

To determine the safety profile and propose the recommended phase 2 dose (RP2D) of autologous CD19-CD22-CAR T cells in patients ≤ 21 years of age with recurrent/refractory CD19- and/or CD22-positive leukemia.

Secondary Objective:

To evaluate the anti-leukemic activity of CD19-CD22-CAR T cells.

Read the detailed description

Treatment will include a single course of lymphodepleting chemotherapy (fludarabine/cyclophosphamide) followed by CAR T cell infusion. CAR T cell dose will be determined by the protocol-defined dose escalation scheme, based on the number of CAR+ T cells and participant weight.

03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Recurrent Acute Lymphoblastic Leukemia
  • Recurrent B Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
Up to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Collection and Manufacturing Eligibility

Inclusion Criteria:

  • Age \<21 years old
  • CD19- and/or CD22-positive acute leukemia defined as:

    *CD19 and/or CD22-positivity confirmed within 2 months and after receipt of any CD19 or CD22-directed therapy

    • Second or greater relapse
    • Any relapse after HCT
    • Refractory disease (primary or in relapse) despite therapy designed to induce remission
  • Estimated of > 12 weeks
  • or Lansky (age-dependent) performance score ≥50 (Appendix A)
  • For females of childbearing age:

    • Not lactating with intent to breastfeed
    • Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment

Exclusion Criteria:

  • Known primary immunodeficiency
  • Known positivity
  • Known to receiving protocol defined lymphodepleting
  • chemotherapy regimen
  • History of reaction to murine protein-containing products

Treatment Eligibility

Inclusion Criteria:

  • Age \< 21 years old
  • Detectable disease in the bone marrow
  • Estimated life expectancy of > 8 weeks
  • Karnofsky or Lansky (age-dependent) performance score > 50 (Appendix A)
  • Adequate cardiac function defined as >40%, or shortening fraction > 25%
  • without evidence of arrhythmia
  • Adequate renal function defined as or radioisotope >50 mL/min/1.73m2 (GFR >40 mL/min/1.73m2 if \<2 years of age)
  • Adequate pulmonary function defined as forced vital capacity (FVC) >50% of predicted value; or pulse oximetry >92% on room air
  • Total \< 3 times the for age, except in subjects with Gilbert's syndrome
  • (ALT) or aspartate aminotransferase (AST) \< 5 times the upper limit of normal for age
  • Has recovered from all NCI CTAE grade III-IV, non-hematologic acute toxicities from prior therapy
  • Prior to planned CAR T cell infusion, patients with a history of prior allogeneicHCT must be at least 3 months from HCT, have no evidence of acute , and have not received a donor lymphocyte infusion (DLI) within the 28 daysprior to planned infusion
  • For females of childbearing age:

    • Not lactating with intent to breastfeed
    • Not pregnant with negative serum or urine pregnancy test within 7 days prior to enrollment
    • If sexually active, agreement to use until 3 months after T cell infusion. Male partners should use a condom.

Exclusion Criteria:

  • Known primary immunodeficiency
  • Known HIV positivity
  • Known contraindication to receiving protocol defined lymphodepleting
  • chemotherapy regimen
  • History of hypersensitivity reactions to murine protein-containing products
  • Severe, uncontrolled bacterial, viral or fungal infection
  • Active CNS-3 disease
  • Evidence of active, uncontrolled neurologic disease
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    CD19-CD22-CAR T cell therapy

    This study has two parts: Collection and Manufacturing Phase - Patients will have white blood cells collected in the St. Jude Blood Donor Center through a procedure called apheresis, or your doctors may use a previously collected frozen product. The collected cells will be engineered to improve their ability to recognize and kill cancer cells. The final cell product is referred to as the CD19-CD22 CAR T cells. Treatment Phase - Eligible patients will receive chemotherapy before receiving the CAR T cells.

    Drug: Fludarabine · Drug: Cyclophosphamide · Drug: Mesna · Device: CD19-CD22 CAR T cell infusion

Interventions

  • IV

  • IV

  • DrugMesna

    IV

  • DeviceCD19-CD22 CAR T cell infusion

    CAR T cell infusion will be given intravenously, either centrally or peripherally.

06

What researchers measure

Primary outcomes

  1. Recommended phase 2 dose (RP2D) of CD19-CD22-CAR T cells

    Phase I design to determine the RP2D of CD19-CD22-CAR T cells. Two (2) dose levels will be evaluated (1x106 and 3x106cells/kg).

    Time frame: up to 4 weeks after CD19-CD22-CAR T-cell infusion

  2. Incidence of adverse events

    Will be assessed and graded using the CTCAE v5.0, with the exception of CRS and ICANS, which will be graded according to ASTCT Consensus Guidelines. Adverse events will be summarized descriptively and dose limiting toxicity (DLT) rate will be reported.

    Time frame: up to 4 weeks after CD19-CD22-CAR T-cell infusion

07

Study locations

1 of 1 sites recruiting
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2025 (actual). Primary completion is estimated for Jan 2030, 57 months after the start.

Of 158 non-industry phase 1 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 92. This study's planned 57 months is close to that.

Counting every sponsor, half of 208 studies reached it within 55 months; a quarter within 34 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2025
First posted
Jan 16, 2025
StartActual
Apr 28, 2025
Primary completionEst.
Jan 2030
CompletionEst.
Jan 2031
Last update
May 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06777979
Responsible party
Sponsor
First posted
Jan 16, 2025
Start date
Apr 28, 2025
Primary completion
Jan 2030 (estimated)
Completion
Jan 2031 (estimated)
Last update
May 19, 2026

Study contacts

Rebecca Epperly, MD
Contact
referralinfo@stjude.org
888-226-4343
Rebecca Epperly, MD
principal investigator · St. Jude Children's Research Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fludarabine · Cyclophosphamide · Mesna

Start the discussion